Sinopsis
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Episodios
-
![Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing]()
Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing
06/01/2023 Duración: 21minFrederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing
-
![Susana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation]()
Susana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation
28/12/2022 Duración: 20minSusana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation
-
![Isabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time]()
Isabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time
28/12/2022 Duración: 37minIsabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time
-
![Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC]()
Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC
14/12/2022 Duración: 20minEgbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC
-
![Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch]()
Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch
05/12/2022 Duración: 27minKjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch
-
![Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?]()
Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?
17/11/2022 Duración: 37minPaolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?
-
![Mohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat]()
Mohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat
01/11/2022 Duración: 21minMohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat
-
![Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022]()
Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022
27/10/2022 Duración: 23minNoemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022
-
![Rana R. McKay, MD - Practice Series on Translating Data Into Practice in mCRPC: The Evolving Role of Radiopharmaceuticals]()
Rana R. McKay, MD - Practice Series on Translating Data Into Practice in mCRPC: The Evolving Role of Radiopharmaceuticals
19/10/2022 Duración: 18minRana R. McKay, MD - Practice Series on Translating Data Into Practice in mCRPC: The Evolving Role of Radiopharmaceuticals
-
![Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC]()
Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC
04/10/2022 Duración: 01h20minContemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC
-
![Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice]()
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice
03/10/2022 Duración: 24minExpert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice
-
![Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC]()
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
29/09/2022 Duración: 27minRight Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
-
![Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit]()
Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit
29/09/2022 Duración: 18minManaging Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit
-
![Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC]()
Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC
20/09/2022 Duración: 24minHot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC
-
![Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care]()
Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
07/09/2022 Duración: 55minReassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
-
![Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions]()
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
07/09/2022 Duración: 20minPersonalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
-
![Question Time: Applying New Therapies for the Management of mTNBC]()
Question Time: Applying New Therapies for the Management of mTNBC
29/08/2022 Duración: 38minQuestion Time: Applying New Therapies for the Management of mTNBC
-
![New Biomarkers, New Targets in Advanced NSCLC]()
New Biomarkers, New Targets in Advanced NSCLC
17/08/2022 Duración: 20minNew Biomarkers, New Targets in Advanced NSCLC
-
![Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias]()
Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias
01/08/2022 Duración: 18minAddressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias
-
![IAP Antagonists in Oncology: What Do We Know?]()
IAP Antagonists in Oncology: What Do We Know?
25/07/2022 Duración: 23minIAP Antagonists in Oncology: What Do We Know?
